Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inclusion body myositis.

Rabi Tawil1, Robert C Griggs

  • 1Department of Neurology, University of Rochester, Rochester, New York 14642, USA. Rabi_Tawil@urmc.rochester.edu

Current Opinion in Rheumatology
|November 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial.

Neurology·2026
Same author

Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD.

Annals of clinical and translational neurology·2026
Same author

Neurobehavioral Profiles in Young Steroid-Naive Boys With Duchenne Muscular Dystrophy: A Baseline Data Analysis From the FOR-DMD Trial.

Neurology·2026
Same author

Motor Function and Growth Outcomes With Early Corticosteroid Initiation in Duchenne Muscular Dystrophy: An Adjusted Cross-Trial Comparison.

Muscle & nerve·2026
Same author

Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroup.

Neuromuscular disorders : NMD·2026
Same author

Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy.

Annals of neurology·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Inclusion body myositis (IBM) is a muscle disorder with unknown causes, possibly involving mitochondrial issues and protein buildup. Current treatments are ineffective, but new therapies like beta-interferon are being explored.

Area of Science:

  • Neurology
  • Immunology
  • Muscle Diseases

Background:

  • Inclusion body myositis (IBM) is a distinct inflammatory myopathy.
  • The exact cause of IBM is still unknown.
  • Evidence challenges a purely immune-mediated etiology, suggesting diverse factors.

Purpose of the Study:

  • To review the current understanding of Inclusion body myositis (IBM) etiology.
  • To discuss the limitations of conventional treatments for IBM.
  • To highlight emerging therapeutic strategies for IBM.

Main Methods:

  • Literature review of studies on IBM pathogenesis.
  • Analysis of evidence for various proposed etiologic factors.
  • Examination of treatment outcomes and ongoing clinical trials.

Related Experiment Videos

Main Results:

  • Etiology of IBM is multifactorial, including mitochondrial DNA deletions, oxidative stress, and abnormal protein accumulation (e.g., Alzheimer-type proteins).
  • Conventional immunosuppressive therapies have shown disappointing results in treating IBM.
  • Emerging treatments under investigation include beta-interferon and anabolic hormones.

Conclusions:

  • The complex and diverse etiologies of IBM necessitate a re-evaluation of treatment strategies.
  • Novel therapeutic approaches targeting specific pathological pathways are crucial for effective IBM management.
  • Further research is needed to elucidate the precise mechanisms driving IBM and to develop targeted therapies.